-

What Our Pupils Reveal: MindMetrix Joins Wyss Geneva to Bring Eye-Based Biofeedback to Mental Health

GENEVA, Switzerland--(BUSINESS WIRE)--We are proud to welcome MindMetrix AG as one of the newest Wyss Geneva ventures. Born out of research at ETH Zurich’s Neural Control of Movement Lab, MindMetrix is a neurotechnology company that reads the brain’s arousal system through the eyes and turns it into live biofeedback, so people can see, and learn to regulate, their own mental state.

We're proud to welcome @MindMetrix as our newest venture. The spin-off reads the brain's arousal system through the eyes and turns it into live biofeedback. #Neurotechnology

Share

The mind is still assessed mostly through questionnaires and self-report, with no objective, real-time measure of brain activity. The size of our pupils changes with the brain’s arousal center, a tiny region deep in the brainstem that is otherwise hard to observe without a brain scan. MindMetrix uses pupillometry to read that signal and turn it into live feedback, giving people a non-invasive window into their own arousal state and a way to train it. Tested in more than 100 participants, the approach has been published in journals including Nature Human Behaviour and Nature Communications.

“Mental health is one of the few areas in medicine that still relies heavily on subjective measures. MindMetrix has shown that a simple, non-invasive signal can objectively measure the brain’s arousal system. Our role now is to help the team turn that science into a tool clinicians can rely on,” said Tracy Laabs, Director of the Wyss Center Geneva.

As a Wyss Geneva venture, MindMetrix is now advancing toward clinical use, starting with disorders marked by arousal dysregulation and focusing first on post-traumatic stress disorder (PTSD), drawing on Wyss Geneva’s engineering, regulatory, clinical and business expertise and its partner network.

“Our first product showed that once people can see their arousal state, they can learn to change it. With Wyss Geneva’s venture-building expertise and early capital, we can now bring this to the patients who need it most,” said Marc Bächinger, CEO and Co-founder of MindMetrix.

About MindMetrix AG

MindMetrix AG is a neurotechnology company making the mind measurable. A spin-off from ETH Zurich’s Neural Control of Movement Lab, it uses pupillometry to read the brain’s arousal system through the eyes and turn it into live biofeedback, so people can see and learn to regulate their own mental state. Its first application, myflow, helps users build mindfulness and mental wellbeing through objective feedback and mental training. As a Wyss Geneva venture, MindMetrix is advancing this technology toward clinical use in mental health, starting with conditions marked by arousal dysregulation. For more information, visit mindmetrix.ch

About Wyss Geneva

Wyss Geneva exists so that breakthroughs in brain science reach the people who need them, sooner. An independent, not-for-profit organization based at Campus Biotech in Geneva, the Center seeks out disruptive science in neuroengineering, de-risks it and backs the entrepreneurs who turn it into companies that change how neurological and mental health disorders are treated. The Center was established in 2014 with the generous support of Swiss entrepreneur and philanthropist Hansjörg Wyss. To learn more, visit wysscenter.ch

Contacts

Media
Wyss Geneva, Aldonza Gübeli – aldonza.gubeli@wysscenter.ch
MindMetrix AG — Veronica Miranda — veronica@mindmetrix.ch

Wyss

Details
Headquarters: Geneva, Switzerland
CEO: - -
Employees: 60
Organization: NON

Release Versions

Contacts

Media
Wyss Geneva, Aldonza Gübeli – aldonza.gubeli@wysscenter.ch
MindMetrix AG — Veronica Miranda — veronica@mindmetrix.ch

Social Media Profiles
More News From Wyss

Wyss Geneva Steps Into Its Next Chapter

GENEVA--(BUSINESS WIRE)--The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to ev...

Wyss Geneva Spin-Off Clee Medical Secures Seed Financing to Bring Real-Time Vision to Brain Surgery

GENEVA,--(BUSINESS WIRE)--The Wyss Center for Bio and Neuroengineering Geneva announced today the successful closing of the Seed financing round of Clee Medical SA, a Swiss neurotechnology spin-off developing ultra-high-resolution real-time intraoperative imaging for brain surgery. The round was led by High-Tech Gründerfonds (HTGF), with participation from Zürcher Kantonalbank (ZKB), Kickfund, FONGIT, and Venture Kick joining existing investors Wyss Center Geneva. Clee Medical spun-out from Wys...

Craig Cook appointed Chief Business Officer and Co-founder at ABILITY Neurotech, the Wyss Geneva’s flagship spin-off

GENEVA--(BUSINESS WIRE)--The Wyss Center for Bio and Neuroengineering proudly announces the appointment of Craig Cook, former Head of Business Development & Licensing at the Center, as Chief Business Officer and Co-founder of ABILITY Neurotech SA, a pioneering spin-off company translating breakthrough brain-computer interface (BCI) technology into clinical impact. During his tenure at the Wyss Center, Craig Cook played a transformative role in establishing a strong business development fram...
Back to Newsroom